Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,235 public trials 1,182 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Active, Not Recruiting

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT06624059

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Royal North Shore Hospital St Leonards, New South Wales, Australia
  • Sir Charles Gairdner Hospital Nedlands, Western Australia, Australia
  • Instituto do Cancer do Estado de Sao Paulo - ICESP São Paulo, Brazil
  • RedSalud Vitacura Santiago, Chile
View Trial Details
Active, Not Recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Memorial Medical Center Modesto, California, United States
  • Community Hospital of Monterey Peninsula Monterey, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Research Site Beverly Hills, California, United States
  • Research Site La Jolla, California, United States
  • Research Site Los Alamitos, California, United States
  • Research Site Los Angeles, California, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Southern Cancer Center PC-Daphne Daphne, Alabama, United States
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
View all 1407 locations
View Trial Details
Active, Not Recruiting

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075

Conditions
Advanced Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • Research Site Denver, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Grand Rapids, Michigan, United States
View Trial Details
Active, Not Recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

NCT04227028

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Northwestern University Chicago, Illinois, United States
  • Rush University Medical Center Chicago, Illinois, United States
View Trial Details
Active, Not Recruiting

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Walnut Creek, California, United States
  • GSK Investigational Site Norwich, Connecticut, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
View all 163 locations
View Trial Details
Active, Not Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site The Bronx, New York, United States
  • Research Site Houston, Texas, United States
  • Research Site Charlottesville, Virginia, United States
  • Research Site Vienna, Austria
View all 49 locations
View Trial Details

Related conditions